EP2040754A1 - Verwendung von fettgewebezellfraktionen zur geweberegeneration nach einer bestrahlung - Google Patents

Verwendung von fettgewebezellfraktionen zur geweberegeneration nach einer bestrahlung

Info

Publication number
EP2040754A1
EP2040754A1 EP07765378A EP07765378A EP2040754A1 EP 2040754 A1 EP2040754 A1 EP 2040754A1 EP 07765378 A EP07765378 A EP 07765378A EP 07765378 A EP07765378 A EP 07765378A EP 2040754 A1 EP2040754 A1 EP 2040754A1
Authority
EP
European Patent Office
Prior art keywords
irradiation
use according
cells
lesions
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP07765378A
Other languages
English (en)
French (fr)
Other versions
EP2040754B1 (de
Inventor
Radia Tamarat
Marc Benderitter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INSTITUT DE RADIOPROTECTION ET DE S??RETE NUCLEAIR
Original Assignee
Institut de Radioprotection et de Surete Nucleaire (IRSN)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut de Radioprotection et de Surete Nucleaire (IRSN) filed Critical Institut de Radioprotection et de Surete Nucleaire (IRSN)
Publication of EP2040754A1 publication Critical patent/EP2040754A1/de
Application granted granted Critical
Publication of EP2040754B1 publication Critical patent/EP2040754B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/60—Materials for use in artificial skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the present invention relates to the use of cells derived from the vascular stroma fraction of extra-medullary adipose tissue to promote tissue regeneration as a result of irradiation-induced lesions.
  • the cicatricial process requires the implementation of complex and perfectly orchestrated biological and molecular mechanisms, such as cell migration, cell proliferation, or extracellular matrix deposition.
  • Induced injury is the starting point for a cascade of events involving interactions between local, regional, and systemic growth factors, as well as participation at the cellular level of different actors including bone marrow stem cells.
  • a disruption in these complex mechanisms has disabling consequences for affected individuals, including physical or quality of life consequences and can even be fatal. This is the case when infections appear and lead in the most serious cases to amputations of limbs, or more generally to heavy surgical procedures.
  • Growth factor therapies have also been considered, particularly with the administration of PDGF-BB and bFGF, or the use of cell therapies. They promote wound repair and can be used alone or in addition to other therapies or surgeries.
  • Techniques employing regenerative cells have been relatively successful. They involve using the ability of stem cells to self-renew indefinitely, and to differentiate into specialized mature cells and tissues. However, these methods require advanced technologies and generate very significant costs due to the availability of raw materials, their obtaining and purification. They are also very dependent on possible phenomena of contamination by microorganisms and relatively important delays for the preparation of raw materials.
  • These cell therapies seem to be the most promising.
  • application US 2003/0082152 (1) describes in a rather general manner methods for preparing adipose tissue-derived stem cells, as well as their pluripotent nature and the interest of these cells for tissue engineering, injury repair. , and tissue regeneration in vivo and ex vivo.
  • the types of injuries for which these cells can be used to promote healing include only mechanical injuries. This document does not indicate anywhere that irradiation-induced lesions can also be treated.
  • radiodermatitis defined as an inflammatory reaction of the skin, equivalent to a burn of the first degree, and then depilation.
  • the dilation of the capillaries also causes acute erythema.
  • a dry and then wet desquamation may appear a few days after irradiation of 10 to 20 Gray and is characterized firstly by a degeneration of keratinocytes at the level of the epidermis leading to its thinning at the flattening of the dermal papillae and on the other hand, by the swelling and proliferation of the vascular endothelium. Late effects result in ischemia probably due to hyperproliferation of surviving epithelial cells causing localized or partial occlusion of arterioles and major fibrosis. These physiological phenomena are not present in mechanically inflicted wound-type skin lesions, which are therefore of a different type from those caused by irradiation.
  • a drug is effective in improving the healing of a mechanically induced injury does not necessarily imply that this drug will be effective for the treatment of lesions, particularly cutaneous lesions, related to irradiation, healing of a post-irradiation lesion involving much more complex mechanisms.
  • stem cells were isolated from embryonic tissues, but recently the presence of pluripotent stem cells has been demonstrated in different adult tissues such as bone marrow, skin, brain, muscles, and bone marrow. adipose tissue. Such stem cells are thus more readily available than embryonic cells, and their use does not have the same ethical problems.
  • the use of stem cells is limited by their low numbers in most adult tissues, and by the difficulty of extracting and purifying them. New pathways have been proposed (3) for obtaining stem cells, in particular from adipose tissue.
  • Adipose tissue can indeed constitute an important reservoir, in which the stem cells are comparatively easy to isolate, and in relatively large quantities. They also make it possible to overcome the existence of a compatible donor as is the case when using cells from the bone marrow. They also make it possible to envisage “auto-grafts", thus avoiding failures related to possible rejections.
  • Adipose tissue exists in different forms in mammals. Extramedullary white adipose tissue, the body's main storage organ, white medullary adipose tissue, and thermogenic brown adipose tissue. White adipose tissue is an abundant source of cells that is easy to obtain. Moreover, its potential persists throughout life. It consists of two cellular fractions: an adipocyte fraction characterized by the accumulation of triglycerides, and composed for the most part of differentiated adipocytes, and a non-adipocyte fraction called vascular stroma fraction (FSV) comprising blood cells, mature endothelial cells, pericytes, fibroblasts, and pluripotent stem cells.
  • FSV vascular stroma fraction
  • the vascular stroma fraction includes, in addition to adipocyte progenitors, hematopoietic and neurogenic progenitors, as well as mesenchymal stem cells capable of differentiating into estrogenic, chondrogenic, and myogenic lineages (4).
  • White adipose tissue has angiogenic properties with applications in autologous cell therapy in a post-traumatic or pathological context.
  • the injection of autologous adipose tissue is particularly performed in surgery to promote the re-vascularization of grafts and the reconstruction of soft tissues.
  • FSV-derived cells have also been administered to promote angiogenesis in the treatment of ischemic conditions.
  • FSV cells represent a heterogeneous population of cells surrounding adipocytes in fatty tissues, and include mature microvascular endothelial cells. This fraction has also been identified as an important source of pluripotent cells capable of differentiating into neurogenic phenotypes, cardiomyocytes, and more recently as having angiogenic activity.
  • FSV is involved in the formation of a matrigel model and increases neovascularization of ischemic tissue (5).
  • adipocyte cell lines have the ability to release important pro-angiogenic factors such as monobutyril, vascular endothelial growth factor (VEGF), and leptin.
  • VEGF vascular endothelial growth factor
  • the Applicant has, surprisingly, demonstrated that cells from the vascular stromal fraction of extra-medullary adipose tissue are of considerable interest in the treatment of lesions in a specific context of post-irradiation.
  • the present invention relates to the use of cells derived from the vascular stroma fraction of extra-medullary adipose tissue for the preparation of a medicament for promoting tissue regeneration as a result of irradiation-induced lesions.
  • the invention relates to the use of cells derived from the vascular stroma fraction of extra-medullary adipose tissue, for the preparation of a medicinal product intended to promote the regeneration of the skin, and in particular o-keratinocytes, the result of injuries caused by irradiations. More particularly, the lesions are skin wounds caused by irradiations.
  • the use of cells derived from the FSV of the extra-medullary adipose tissue makes it possible to act by accelerating the closure of the scars, by acting on the differentiation of the keratinocytes, and / or the viscoelasticity of the skin, in particular by increasing the collagen production. It has the advantage of being able to have a very large quantity of tissues and cells and does not pose any particular ethical problems. It is also possible to envisage homologous or heterologous transplants, and the ability to treat several people from a single patient. only individual. The implementation of the use according to the invention is greatly facilitated by the origin of the cells used. Indeed it is possible to maintain, multiply or even immortalize the cells in vitro in a defined medium. It is conceivable to maintain the frozen cells and build up available cell stocks.
  • the tissues are more rapidly protected from any external pathogenic agent.
  • the present invention relates to the use of cells derived from the vascular stroma fraction of extra-medullary adipose tissue to promote tissue regeneration as a result of irradiation-induced lesions in tissues selected from skin, bone , the brain, the neck, the intestine, the breasts, the heart, the lungs, the uterus and the rectum.
  • the use of cells derived from the vascular stromal fraction of extra-medullary adipose tissue according to the present invention finds application in many fields.
  • the radiation responsible for the lesions can be accidental, or caused by radiotherapy treatments. This is particularly the case for cancer patients.
  • the medicaments used in the context of the present invention may be used for preventive and administered before irradiation. They can of course also be used for curative purposes, and administered after irradiation.
  • Adipose tissue cells are obtained directly from adipose tissue fragments taken under anesthesia. After enzymatic digestion of the extracellular matrix, the different cell populations are selected by difference of density or by difference of expression of antigens. The stromal-vascular fraction used for the implementation of the present invention not containing the adipocytes is thus isolated.
  • the cells are obtained by the following successive steps: extraction of a sample of extra-medullary adipose tissue, isolation according to the methods described by Bjorntorp et al (6) of the cellular fraction of the vascular stroma by digestion of the matrix with proteolytic enzymes, and by density gradient separation, cell purification by physical separation and / or immunoselection.
  • the physical separation is carried out by difference of adhesion on a solid support, and the immunoselection is carried out using several antibodies specific for the markers expressed by the adipocyte precursors (CD 34 +, CD45- and CD31-).
  • the cells derived from the FSV of extra-medullary adipose tissue are used according to the invention to prepare a medicament in the form of a pharmaceutical composition containing the cells derived from the vascular stroma fraction of extra-medullary adipose tissue, and at least a pharmaceutically acceptable carrier and / or carrier.
  • This pharmaceutical composition is suitable for any form of administration usually envisaged.
  • the pharmaceutical forms there may be mentioned more particularly those which are suitable for parenteral, per- or transdermal administration, creams, ointments, sprays, gels, ampoules and / or injectable solutions.
  • the dosage varies with the age and weight of the patient, the route of administration, or any associated treatments.
  • the use of cells derived from the vascular stroma fraction of extra-medullary adipose tissue is intended for the preparation of a medicament in the form of a spray, a gel, or an injectable solution.
  • these pharmaceutical compositions can be in the form of aerosols.
  • cells from the stroma-vascular fraction of extramedullary adipose tissue are used for the preparation of dermal equivalents, such as the INTEGRA ®, and for promoting tissue regeneration following injury caused by irradiation.
  • dermal equivalents such as the INTEGRA ®
  • These equivalent dermas are intended to administer the cells in a collagen matrix that constitutes INTEGRA ® .
  • the polymeric or copolymeric support is solid or semi-solid
  • INTEGRA ® is an artificial skin, or skin regeneration structure. It is a double layer membrane system aimed at skin replacement.
  • the dermal replacement layer is made in particular from a porous matrix of crosslinked bovine tendon collagen fibers and a glyscosaminoglycan whose porosity is controlled and the rate of degradation defined during its manufacture. More particularly, in this aspect, equivalent Dermes are useful in the treatment of burns caused by irradiation.
  • Figure 1 Observation of the evolution of the scar of mice in a pathological context, post-irradiation.
  • Figure 2 Observation of the evolution of the mouse scar in a physiological context, without irradiation.
  • Figure 3 Histograms of remaining scarring measurements at Day 14 (Fig. 3A), and viscoelasticity at Day 14 (Fig. 3B).
  • a fragment of adipose tissue is removed from the subcutaneous adipose tissue in the mouse under anesthesia.
  • proteolytic enzymes at 37 ° C. in collagenase for 45 min, to allow dissociation of the cells of the tissue, the different cell populations are selected by difference in density according to the methods described by Bjorntorp. and al (6) or by difference in expression of antigens.
  • the cell fraction that does not contain the adipocytes corresponds to the fraction of the vascular stroma. These cells are labeled CD 34 +, CD 45- and CD 31.
  • Localized irradiation of 20 Gy is performed on the dorsal surface of the animal after shaving and anaesthetizing the mice. This irradiation is performed before the application of a punch.
  • a 0.8 mm diameter punch is applied to the dorsal surface of 8 week old male mice (C57B16, IfFa Creddo) to produce a wound.
  • the cells obtained in Example 1 are injected locally (loc) or intravenously (iv).
  • the animals receive IxIO 6 cells and the controls receive the solvent, phosphate buffered saline.
  • Each group of experience consists of 5 individuals.
  • a 2 mm probe is applied to aspirate the dorsal skin of the animal and estimate the cutaneous viscoelasticity parameter at the regenerated tissue.
  • the application of the probe makes it possible to perform a suction and then a relaxation of the skin.
  • the deformation of the skin is estimated with the help of an optical measurement system that allows to deliver a graph with measurements of elasticity and skin relaxation.
  • the measurements are carried out in parallel in a pathological context, on animals having been irradiated, and in a physiological context, on animals which have not undergone prior irradiation.
  • the results of the viscoelastic measurements are reported in Table (II) below, expressed in arbitrary units.
  • tissue repair in a post-irradiation setting is late, and reconstitution is only partial. Indeed at the end of the process, (J14) the opening surface of the wound remains important.
  • mice that received FSV cells from extra-medullary adipose tissue completely reconstituted their skin with complete closure of the wound and improved skin quality, and more specifically, viscoelasticity.
  • the slowing observed during closure of wounds caused in a post-irradiation context is completely eliminated by the use of the FSV cells of the extra-medullary adipose tissue according to the invention, and the values observed show that the acceleration of the healing process obtained after the administration of these cells in an irradiation context makes it possible to obtain a wound comparable to that it is observed in a situation of normal physiological healing.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Botany (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
EP07765378A 2006-06-12 2007-06-12 Verwendung von fettgewebezellfraktionen zur geweberegeneration nach einer bestrahlung Active EP2040754B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0605190A FR2902011B1 (fr) 2006-06-12 2006-06-12 Utilisation de fractions cellulaires du tissu adipeux pour la regeneration tissulaire post irradiation
PCT/EP2007/055782 WO2007144358A1 (fr) 2006-06-12 2007-06-12 Utilisation de fractions cellulaires du tissu adipeux pour la regeneration tissulaire post irradiation

Publications (2)

Publication Number Publication Date
EP2040754A1 true EP2040754A1 (de) 2009-04-01
EP2040754B1 EP2040754B1 (de) 2012-01-25

Family

ID=37651021

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07765378A Active EP2040754B1 (de) 2006-06-12 2007-06-12 Verwendung von fettgewebezellfraktionen zur geweberegeneration nach einer bestrahlung

Country Status (8)

Country Link
US (1) US8173119B2 (de)
EP (1) EP2040754B1 (de)
JP (1) JP5251873B2 (de)
AT (1) ATE542547T1 (de)
CA (1) CA2654021C (de)
ES (1) ES2377993T3 (de)
FR (1) FR2902011B1 (de)
WO (1) WO2007144358A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016140716A1 (en) 2015-03-02 2016-09-09 The Trustees Of Columbia University In The City Of New York Injectable microtissue systems, devices, and methods
JP7393085B2 (ja) * 2018-05-25 2023-12-06 ポーラ化成工業株式会社 皮下組織の酸素レベルの推定方法、推定装置及び推定プログラム、並びに、皮下組織の粘弾性又は皮下脂肪細胞の線維化レベルの推定方法、推定装置及び推定プログラム
JP7412901B2 (ja) * 2018-06-05 2024-01-15 ポーラ化成工業株式会社 脂肪細胞を包む線維構造の線維化レベルの推定方法、推定装置及び推定プログラム、並びに、皮下組織の粘弾性の推定方法、推定装置及び推定プログラム

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3765301A (en) * 1968-06-09 1973-10-16 Us Army Light weight ribbed composite armor
US20030082152A1 (en) * 1999-03-10 2003-05-01 Hedrick Marc H. Adipose-derived stem cells and lattices
AU2001238695B2 (en) * 2000-02-26 2005-11-24 Artecel Sciences, Inc. Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof
FR2819265B1 (fr) * 2001-01-10 2004-01-02 Centre Nat Rech Scient Cellules du tissu adipeux extramedullaire et leurs applications dans la reconstitution des lignees hematopoietiques
US20050107876A1 (en) 2002-09-30 2005-05-19 Kim Ki-Ho Dermal substitute consisting of amnion and biodegradable polymer, the preparation method and the use thereof
CA2532542A1 (en) * 2003-07-18 2005-01-27 Regenerx Biopharmaceuticals, Inc. Treatment or prevention of damage due to radiation exposure
FR2859381B1 (fr) 2003-09-05 2008-07-25 Centre Nat Rech Scient Utilisaton de cellules issues du tissu adipeux pour induire la formation d'un reseau vasculaire fonctionnel
US9453202B2 (en) 2003-10-08 2016-09-27 Vet-Stem, Inc. Methods of preparing and using novel stem cell compositions and kits comprising the same
PL1778833T3 (pl) * 2004-07-01 2011-10-31 Cytori Therapeutics Inc Sposoby stosowania komórek regeneracyjnych w celu przyspieszania gojenia się ran

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007144358A1 *

Also Published As

Publication number Publication date
FR2902011B1 (fr) 2008-12-26
US8173119B2 (en) 2012-05-08
JP2009539520A (ja) 2009-11-19
FR2902011A1 (fr) 2007-12-14
ES2377993T3 (es) 2012-04-04
WO2007144358A1 (fr) 2007-12-21
ATE542547T1 (de) 2012-02-15
CA2654021C (fr) 2014-03-11
JP5251873B2 (ja) 2013-07-31
CA2654021A1 (fr) 2007-12-21
EP2040754B1 (de) 2012-01-25
US20100233134A1 (en) 2010-09-16

Similar Documents

Publication Publication Date Title
Mohanty et al. A human epidermal growth factor-curcumin bandage bioconjugate loaded with mesenchymal stem cell for in vivo diabetic wound healing
Las Heras et al. Chronic wounds: Current status, available strategies and emerging therapeutic solutions
Li et al. Human keratinocyte-derived microvesicle miRNA-21 promotes skin wound healing in diabetic rats through facilitating fibroblast function and angiogenesis
Sun et al. Conduits harnessing spatially controlled cell-secreted neurotrophic factors improve peripheral nerve regeneration
Werber Amniotic tissues for the treatment of chronic plantar fasciosis and Achilles tendinosis
KR20040111355A (ko) 미분화 태아 세포를 포함하는 피부 질환 치료용 조성물
Hong et al. Hair grows hair: Dual-effective hair regrowth through a hair enhanced dissolvable microneedle patch cooperated with the pure yellow light irradiation
JP2011528352A (ja) 創傷の治癒
JP6532452B2 (ja) ポリ−ｎ−アセチルグルコサミンナノファイバーを有する疾患の処置
Izadi et al. Synergistic effect of high-intensity interval training and stem cell transplantation with amniotic membrane scaffold on repair and rehabilitation after volumetric muscle loss injury
Xu et al. miR-126-3p-loaded small extracellular vesicles secreted by urine-derived stem cells released from a phototriggered imine crosslink hydrogel could enhance vaginal epithelization after vaginoplasty
EP2040754B1 (de) Verwendung von fettgewebezellfraktionen zur geweberegeneration nach einer bestrahlung
KR20210021165A (ko) 지방줄기세포 유래 스페로이드를 포함하는 조건 배지를 유효성분으로 포함하는 상처 치유용 약학 조성물
Zhang et al. PLGA@ IL-8 nanoparticles-loaded acellular dermal matrix as a delivery system for exogenous MSCs in diabetic wound healing
Zhu et al. Construction of adipose tissue using a silica expander capsule and cell sheet-assembled of decellularized adipose tissue
CA2839760C (fr) Utilisation de composes oligosaccharidiques pour la prevention et le traitement des cicatrices pathologiques
Wen et al. In situ precision cell electrospinning as an efficient stem cell delivery approach for cutaneous wound healing
KR101816964B1 (ko) 피부 또는 혈관조직 손상 치료 보조용 약학 조성물
CN114869841B (zh) 一种携载干细胞活性生物因子和大剂量曲安奈德的微针贴片及其制备方法
US20220339202A1 (en) Regenerative bioactive suspension derived from freshly disaggregated tissue and methods of use in clinical therapies
FR2637501A1 (fr) Composition stabilisee a base de facteurs de croissance de la famille fgf et de dextrane sulfate, et ses applications
Heidari et al. Effects of hair follicle stem cells coupled with polycaprolactone scaffold on cutaneous wound healing in diabetic male rats
TWI608839B (zh) 治療肌腱炎之醫藥組合物及其製備方法
US20220062501A1 (en) Decellularized fetal matrix for tissue regeneration
Capoano et al. Multidisciplinary Approaches to the Stimulation of Wound Healing and Use of Dermal Substitutes in Chronic Phlebostatic Ulcers

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081210

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

RIN1 Information on inventor provided before grant (corrected)

Inventor name: TAMARAT, RADIA

Inventor name: BENDERITTER, MARC

17Q First examination report despatched

Effective date: 20090402

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: INSTITUT DE RADIOPROTECTION ET DE S??RETE NUCLEAIR

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

DAX Request for extension of the european patent (deleted)
GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 542547

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120215

Ref country code: CH

Ref legal event code: NV

Representative=s name: MICHELI & CIE SA

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602007020274

Country of ref document: DE

Effective date: 20120322

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2377993

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20120404

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20120125

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120425

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120125

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120525

REG Reference to a national code

Ref country code: IE

Ref legal event code: FD4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120125

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120525

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120125

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120426

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120125

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 542547

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120125

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120125

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120125

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120125

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120125

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120125

Ref country code: IE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120125

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120125

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120125

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120125

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

BERE Be: lapsed

Owner name: INSTITUT DE RADIOPROTECTION ET DE SURETE NUCLEAIRE

Effective date: 20120630

26N No opposition filed

Effective date: 20121026

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602007020274

Country of ref document: DE

Representative=s name: KILIAN KILIAN & PARTNER, DE

Ref country code: DE

Ref legal event code: R082

Ref document number: 602007020274

Country of ref document: DE

Representative=s name: KILIAN KILIAN & PARTNER MBB PATENTANWAELTE, DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120125

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120630

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602007020274

Country of ref document: DE

Effective date: 20121026

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120125

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120125

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120612

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070612

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20150612

Year of fee payment: 9

Ref country code: CH

Payment date: 20150605

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20150521

Year of fee payment: 9

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20160617

Year of fee payment: 10

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602007020274

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20160701

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160630

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170103

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160701

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20170612

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170612

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20220629

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20220727

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230628

Year of fee payment: 17